Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

Table 4 Clinical trials and case studies using Sunitinib and Imatinib in relapsed/refractory germ cell tumors

Drug	Study center/Group	Number	Efficacy	Author	Reference
Sunitinib	Canadian Urologic Oncology Group/German	33	3 PR + 1 uPR RR = 13% 6-mo PFS 11%	K. Oechsle et al.	[40]
Sunitinib	Testicular Cancer Study Group cooperative study	33	3 PR + 1 uPR RR = 13% 6-mo PFS 11%	K. Oechsle et al.	[40]
Sunitinib	Memorial Sloan Kettering Cancer Center	10	0 RR, 5 SD	Feldman et al.	[38]
Sunitinib	Hospital de Dénia, Marina Salud	1	1 SD, B-HCG drop	Gasent Blesa, J. M.et al.	[41]
Sunitinib	MD Anderson Cancer Center	5	1 /5PR	Subbiah et al.	Journal of Hem/Onc
Imatinib	Indiana University	6	0/6 1 SD 3 mo with > 50% ↓AFP_	Einhorn et al.	[42]
Imatinib	General Hospital Attikon, University of Athens	1	1 CR ~32 mo	Pectasides, D.et al.	[43]
Imatinib	Central Hospital of Bolzano, Bolzano, Italy	1	1 CR ~ 24 mo	Pedersini R et al.	[44]

PR- Partial response, PFS – Progression free survival, uPR-unconfirmed partial response, SD- Stable disease, CR – Complete Response.

ISSN: 1756-8722